Collagen Triple Helix Repeat Containing 1 Deficiency Protects Against Airway Remodeling and Inflammation in Asthma Models In Vivo and In Vitro
- PMID: 36640227
- DOI: 10.1007/s10753-022-01781-3
Collagen Triple Helix Repeat Containing 1 Deficiency Protects Against Airway Remodeling and Inflammation in Asthma Models In Vivo and In Vitro
Abstract
Asthma is a chronic inflammatory disease characterized by airway remodeling and lung inflammation. Collagen triple helix repeat containing 1 (CTHRC1), a glycoprotein, is involved in multiple pathological processes, including inflammation and fibrosis. However, the function of CTHRC1 in asthma remains unclear. In the present study, the mouse asthma model was successfully generated by sensitizing and challenging mice with ovalbumin (OVA). CTHRC1 expression at both RNA and protein levels was significantly upregulated in lung tissues of asthmatic mice. Asthmatic mice exhibited significant airway remodeling as evidenced by increased bronchial wall and smooth muscle cell layer thickness, goblet cell hyperplasia and collagen deposition, and epithelial-mesenchymal transition (EMT), but those characteristics were reversed by CTHRC1 silencing. The cell model with transforming growth factor-β1 (TGF-β1) induction in bronchial epithelial cells (BEAS-2B) was conducted to verify the effects of CTHRC1 on EMT, a classic mechanism that mediates airway remodeling. The results showed that TGF-β1 stimulation increased CTHRC1 expression, and CTHRC1 knockdown inhibited TGF-β1-induced EMT. OVA-treated mice also showed increased inflammatory cell infiltration and the production of OVA-specific immunoglobulin E (IgE), interleukin (IL)-4, IL-5, and IL-13, which were decreased by CTHRC1 downregulation. The effects of CTHRC1 on OVA-induced airway inflammation were further determined by treating BEAS-2B cells with IL-13, in which CTHRC1 knockdown reduced the IL-13-induced secretion of pro-inflammatory factors, including IL-4 and IL-5. In conclusion, these results indicate that CTHRC1 silencing attenuates asthmatic airway remodeling and inflammation in vivo and in vitro, suggesting that CTHRC1 may be a potential target for asthma treatment.
Keywords: Airway remodelling; Asthma; CTHRC1; EMT; Inflammation.
© 2023. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Similar articles
-
ADP Ribosylation Factor 6 Relieves Airway Inflammation and Remodeling by Inhibiting Ovalbumin Induced-Epithelial Mesenchymal Transition in Experimental Asthma, Possibly by Regulating of E2F Transcription Factor 8.Immunol Invest. 2023 Nov;52(6):717-734. doi: 10.1080/08820139.2023.2222778. Epub 2023 Jun 16. Immunol Invest. 2023. PMID: 37326141
-
Dioscin exhibits protective effects on in vivo and in vitro asthma models via suppressing TGF-β1/Smad2/3 and AKT pathways.J Biochem Mol Toxicol. 2022 Aug;36(8):e23084. doi: 10.1002/jbt.23084. Epub 2022 Apr 28. J Biochem Mol Toxicol. 2022. PMID: 35481609
-
Protective effects and active ingredients of Salvia miltiorrhiza Bunge extracts on airway responsiveness, inflammation and remodeling in mice with ovalbumin-induced allergic asthma.Phytomedicine. 2019 Jan;52:168-177. doi: 10.1016/j.phymed.2018.09.170. Epub 2018 Sep 17. Phytomedicine. 2019. PMID: 30599896
-
Approach for Elucidating the Molecular Mechanism of Epithelial to Mesenchymal Transition in Fibrosis of Asthmatic Airway Remodeling Focusing on Cl- Channels.Int J Mol Sci. 2023 Dec 25;25(1):289. doi: 10.3390/ijms25010289. Int J Mol Sci. 2023. PMID: 38203460 Free PMC article. Review.
-
[Advances in pathogenesis of asthma airway remodeling and intervention mechanism of traditional Chinese medicine].Zhongguo Zhong Yao Za Zhi. 2025 Apr;50(8):2050-2070. doi: 10.19540/j.cnki.cjcmm.20241212.705. Zhongguo Zhong Yao Za Zhi. 2025. PMID: 40461218 Review. Chinese.
Cited by
-
CTHRC1: a key player in colorectal cancer progression and immune evasion.Front Immunol. 2025 Mar 25;16:1579661. doi: 10.3389/fimmu.2025.1579661. eCollection 2025. Front Immunol. 2025. PMID: 40201173 Free PMC article. Review.
References
-
- Papi, A., C. Brightling, S.E. Pedersen, and H.K. Reddel. 2018. Asthma. Lancet (London, England) 391: 783–800. - PubMed
-
- Holgate, S.T., S. Wenzel, D.S. Postma, S.T. Weiss, H. Renz, and P.D. Sly. 2015. Asthma. Nature Reviews Disease Primers 1: 15025. - PubMed
-
- Wang, K.C.W., G.M. Donovan, A.L. James, and P.B. Noble. 2020. Asthma: Pharmacological degradation of the airway smooth muscle layer. The International Journal of Biochemistry & Cell Biology 126: 105818.
-
- Finotto, S. 2019. Resolution of allergic asthma. Seminars In Immunopathology 41: 665–674. - PubMed
-
- Morimoto, Y., K. Hirahara, M. Kiuchi, T. Wada, T. Ichikawa, T. Kanno, M. Okano, K. Kokubo, A. Onodera, D. Sakurai, Y. Okamoto, and T. Nakayama. 2018. Amphiregulin-producing pathogenic memory T helper 2 cells instruct eosinophils to secrete osteopontin and facilitate airway fibrosis. Immunity 49: 134-150.e6. - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical